New Elemental Impurities Tests for Pharmaceutical Products According to the New ICH Q3D and USP 232/233 Guidelines
Website https://www.complianceonline.com/new-elemental-impurities-tests-for-pharmaceutical-products-accordin |
Edit Freely
Category
Deadline: June 27, 2018 | Date: June 27, 2018
Venue/Country: online event, U.S.A
Updated: 2018-06-10 04:02:10 (GMT+9)
Call For Papers - CFP
Areas Covered in the Webinar:Elemental Impurities: The case for changeRegulatory status: FDA, ICH Q3D, USP 232/233Scope of the new guidance on Elemental Impurities - related to ICH Q3D and USP Chapters 232 and 233What drug products are within the scope of the guidanceWhich classes of drug products need to comply with ICH Q3D and which with USP 232/233How risk assessment influences what testing is requiredWhat documentation related to control of elemental impurities is expected by FDAImplementation of the GuidelinesWhich procedures can be used to demonstrate complianceAnalytical Procedures and how methods should be validatedWhat you should be doing now?Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.